HSBC Maintains Buy on AbbVie, Raises Price Target to $315

Benzinga Newsdesk www.benzinga.com Positive 75.7%

Neg 0% Neu 0% Pos 75.7%

HSBC analyst Rajesh Kumar maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $300 to $315.

Comments

No comments yet. Be the first!